>> DTI recently announced an agreement with Fujisawa Healthcare, Inc. to develop an injectable form of DTI-0009. DTI will conduct the Phase I clinical trial while Fujisawa will be responsible for the remaining clinical development and commercialization
of this product. Fujisawa has exclusive rights to the injectable product in the United States and Canada. DTI retains
international rights for the injectable formulation and worldwide rights for the oral formulation. <<
Update.........
Aderis Pharmaceutical, which has an S-1 out.......
DTI-0009 is an adenosine A\\1\\ agonist designed to control heart rate in
atrial fibrillation by slowing conduction through the atrioventricular
node. Atrial fibrillation is the most common of the cardiac arrhythmias, or
abnormal heart rhythms, and affects approximately six million patients
worldwide. DTI-0009 is being developed as both an oral formulation for
chronic and an intravenous
formulation for acute therapy. Fujisawa Healthcare has the exclusive,
clinical development and commercialization rights, in the United States and
Canada, for the intravenous formulation of DTI-0009. The intravenous
formulation of DTI-0009 is in Phase II clinical trials in the United States.
DTI-0017 is an adenosine A\\1\\ antagonist designed to treat edema
typically associated with congestive heart failure. Approximately 4.7
million people in the United States suffer from congestive heart failure.
DTI-0017 is being developed as both an oral formulation for chronic and an
intravenous formulation for acute therapy. Our own studies and other
published research suggest that adenosine A\\1\\ antagonists, such as
DTI-0017, appear to act at a different site in the kidney from most
diuretics, does not affect potassium balance, appear to prevent the
decreased renal function seen with some other diuretics and may prevent the
development of resistance to the diuretic effect occurring with some other
agents. We have concluded our first Phase I clinical trial and are
currently reformulating the product candidate and conducting additional
animal testing.
and from the S-1, clarifying everything.......
We were incorporated as Discovery Therapeutics, Inc. in Delaware in 1994 and
changed our name to Aderis Pharmaceuticals, Inc. in January 2002. Our principal
executive offices are located at 85 Main Street, Hopkinton, Massachusetts
01748 |
